AstraZeneca PLC (BVMF:A1ZN34)

Brazil flag Brazil · Delayed Price · Currency is BRL
165.04
+0.39 (0.24%)
At close: Feb 6, 2026
20.91%
Market Cap1.55T +22.9%
Revenue (ttm)309.78B +13.5%
Net Income50.09B +44.7%
EPS32.08 +45.0%
Shares Outn/a
PE Ratio31.02
Forward PE19.14
Dividend2.77 (1.68%)
Ex-Dividend DateAug 7, 2025
Volume4,337
Average Volume547
Open167.40
Previous Close164.65
Day's Range164.79 - 168.79
52-Week Range123.80 - 177.60
Beta0.19
RSI50.28
Earnings DateFeb 10, 2026

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]

Sector Healthcare
Founded 1992
Employees 94,300
Stock Exchange Brazil Stock Exchange
Ticker Symbol A1ZN34
Full Company Profile

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD Financial Statements